Researchers led by Davide Incarnato at the University of Groningen have demonstrated that the FDA-approved cancer drug ...

Tempus AI sits in the middle of a wide price target range, with some recent bullish initiations reaching up to US$100 per share while others have shifted expectations into the US$60 to US$70 band.

Neutrophil infiltration is a hallmark of pulmonary inflammation during respiratory viral infections, yet the origin of these ...

Neutrophil infiltration is a hallmark of pulmonary inflammation during respiratory viral infections, yet the origin of these cells has been a subject ...

Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...

Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right ...

When veterinary chemotherapy failed to stop Rosie – his rescue dog – from succumbing to aggressive mast cell cancer, Paul ...

Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...

AppLoving (APP) jumped 11.2% last week while Tempus AI (TEM) jumped 11%. Micro was another strong gainer, with a 4% gain in the past week. We review the biggest storylines in AI and why these stocks ...

It hasn't been a strong 2026 for AppLovin, but last week did provide some relief. AppLovin surged to lead the sector after Morgan Stanley raised its price target, maintaining an Overweight rating.